IL DONG PHARMACEUTICAL CO., LTD.
KOSPI
₩15,320.00
-1.29%
Delayed · cached 15 min
Fair value analysis
249420
IL DONG PHARMACEUTICAL CO., LTD.
₩15,320.00
Close used for this calculation
₩10,159.91Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
30/100
Quality radar
Consensus fair value
₩10,159.91
Above FV▼ -33.7% against the close used
Model range ₩3,951.68 – ₩18,840.00
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₩3,951.68Fair value₩10,159.91Bull₩18,840.00
FairClose
52-week traded range
52W low ₩12,150.0052W high ₩44,300.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
IL DONG PHARMACEUTICAL CO., LTD. closed at ₩15,320.00, 50.8% above the consensus fair value of ₩10,159.91 drawn from 7 valuation models.
Financial DNA score 30/100 — Weak. P/E of 16.3x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₩3,951.68
-74.2%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₩12,871.17
-16.0%
√(22.5 × EPS × BVPS)
EPS=942, BVPS=7816.33 · outside Graham range (P/E 16.3, P/B 2) — asset-light, treat as a rough floor
P/E Fair Value
₩18,840.00
+23.0%
EPS × 20x (sector P/E)
EPS=942, Sector P/E=20x
EV/EBITDA
₩7,742.19
-49.5%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=19.48B
Book Value (P/B)
₩9,189.77
-40.0%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=7816.33, ROE=11.2%, g=3%, r=10%
Reverse DCF
₩15,320.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 4.4% | Historical: 0%
Margin of Safety
₩8,915.71
-41.8%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=11887.62, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.